Authors

• Robert Landewé (ORCID: https://orcid.org/0000-0002-0577-6620)
• Barbara Ink
• Akihiko Asahina (ORCID: https://orcid.org/0000-0001-6127-3182)
• Yoshiya Tanaka (ORCID: https://orcid.org/0000-0002-0807-7139)
• Christopher T. Ritchlin (ORCID: https://orcid.org/0000-0002-2602-1219)
• Jason Coarse
• Rajan Bajracharya (ORCID: https://orcid.org/0009-0000-7857-8783)
• Joseph Frank Merola (ORCID: https://orcid.org/0000-0001-6514-4353)
• Iain B. McInnes (ORCID: https://orcid.org/0000-0002-6462-4280)
• Philip J. Mease (ORCID: https://orcid.org/0000-0002-6620-0457)
• Laura C. Coates (ORCID: https://orcid.org/0000-0002-4756-663X)
• Laure Gossec (ORCID: https://orcid.org/0000-0002-4528-310X)
• Andrea Heinrichs
• Vishvesh Shende

Institutions

• Jikei University School of Medicine (JP)
• Brigham and Women's Hospital (US)
• Harvard University (US)
• Inserm (FR)
• University of Occupational and Environmental Health Japan (JP)
• Providence College (US)
• University of Washington (US)
• Sorbonne Université (FR)
• University of Oxford (GB)
• Swedish Medical Center (US)
• Assistance Publique – Hôpitaux de Paris (FR)
• Pitié-Salpêtrière Hospital (FR)
• UCB Pharma (United States) (US)
• Zuyderland Medisch Centrum (NL)
• Institut Pierre Louis d‘Épidémiologie et de Santé Publique (FR)
• UCB Pharma (United Kingdom) (GB)
• Oxford BioMedica (United Kingdom) (GB)
• Oxford University Hospitals NHS Trust (GB)
• UCB Pharma (Germany) (DE)
• University of Rochester (US)
• University of Glasgow (GB)

Publication Details

Journal

Rheumatology and Therapy

Published

2024-08-31

DOI

https://doi.org/10.1007/s40744-024-00708-8

Citations

15

Primary Topic

Spondyloarthritis Studies and Treatments

Type

article

Field-Weighted Citation Impact

7.05

Funders

• Amgen
• Bristol-Myers Squibb
• Eli Lilly and Company
• Pfizer
• AstraZeneca
• Gilead Sciences
• Biogen
• Celgene
• Taiho Pharmaceutical
• Torii Pharmaceutical
• Celltrion
• Eisai
• Mitsubishi Tanabe Pharma Corporation
• Sun Pharma
• LEO Pharma
• UCB Pharma